| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8656890 | Atherosclerosis | 2018 | 8 Pages |
Abstract
Simvastatin and Ezetimibe treatment impeded the progression of the time-related increase in plasma suPAR levels. Year-1 suPAR was associated with all-cause mortality, MCE, and AVE irrespective of baseline levels (SEAS study: NCT00092677).
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Gethin W. Hodges, Casper N. Bang, Julie L. Forman, Michael H. Olsen, Kurt Boman, Simon Ray, Y. Antero Kesäniemi, Jesper Eugen-Olsen, Anders M. Greve, Jørgen L. Jeppesen, Kristian Wachtell,